Articles By Gail Dutton
-
Cutting Regulatory Red Tape?
3/12/2011
There is a growing sense among life science executives that regulators, including the U.S. Congress, are schizoid, promoting innovation amidst policies that stifle R&D and investment. Even a cursory look at the U.S. regulatory situation reveals a Kafka-esque environment of conflicting, sometimes outdated, regulations that drain investment funds and make it unnecessarily difficult to conduct efficient business.
-
Seed Capital: Beyond Angels And VC
1/11/2011
When bootstrapped Covella Pharmaceuticals, Inc. needed a fresh influx of capital last fall, it approached larger biopharmas and was acquired by Santarus. When Taiga Biotechnologies, Inc. needed seed funding in 2006, it turned — like most start-ups — first to family and friends. Then it applied for government grants and cultivated super angels.
-
Biotech Innovation And Access To Capital In An Era Of Reform
1/11/2011
In an era of healthcare reform, legislative initiatives and incentives are countering each other, creating a high level of uncertainty that is causing investors to watch from the sidelines and life sciences companies to seek safer, more assured business strategies. “We live in a policy biopolar world,” Alan Eisenberg, executive VP, emerging companies and business development at BIO, acknowledges, speaking at the BIO-Europe International Partnering Conference in Munich last November.